A phase 3, randomized, double-blind, placebo-controlled study evaluating efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravis (UCB MG0003)

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 3-arm, repeat dose study evaluating the efficacy and safety of two doses of rozanolixizumab and matching placebo in patients with generalized MG who experience moderate to severe symptoms (Myasthenia Gravis Foundation of America [MGFA II-IVa]) and are being considered for additional treatment such as IVIg or PEX

UCB Biopharma SPRL
Principal Investigator(s)
Dr. Henry Kaminski
Contact Phone Number
Request Information

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.